Related Experiment Video
Updated: Aug 14, 2026

A Low Mortality Rat Model to Assess Delayed Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage
Published on: January 17, 2013
Role of MAPK in chronic cerebral vasospasm
K Aoki1, A Y Zubkov, R E Tibbs
1Department of Neurosurgery, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Abstract:
This study was undertaken to investigate the role of p44/42 MAPK in a dog double hemorrhage model of subarachnoid hemorrhage (SAH), and whether MEK inhibitors can alter the degree of SAH-induced vasoconstriction. The diameter of the basilar artery, which was compared with day 0 angiogram, decreased gradually in a time-dependent manner from day 3 (80%), day 5 (68%) through day 7 (53.5%). The level of MAPK (p44/42) immunoprecipitation peaked on day 3 and remained enhanced through day 7 (P < 0.05). MEK inhibitor PD98059 significantly reduced p44/42 MAPK immunoprecipitation and significantly reversed vasospasm and increased residual diameter to 79.0% on day 7. These results demonstrated that p44/42 MAPK kinase is involved in the pathogenesis of cerebral vasospasm. The MEK inhibitor PD98059 might be useful in the treatment of vasospasm.
Related Concept Videos
MAPK Signaling Cascades
Vascular Spasm
Ischemic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology

